Levofloxacin Alert: When the Cure Causes a Crisis
"Understanding DRESS/DIHS, a rare but serious reaction to a common antibiotic, and its connection to autoimmune conditions."
Antibiotics are essential weapons in our fight against bacterial infections. Levofloxacin is a common antibiotic prescribed for a range of conditions. However, like all medications, it carries the risk of side effects. In rare instances, it can trigger a severe and potentially life-threatening reaction known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also referred to as Drug-Induced Hypersensitivity Syndrome (DIHS).
DRESS/DIHS is characterized by a constellation of symptoms, including fever, skin rash, internal organ involvement, and abnormal blood cell counts (eosinophilia). It typically emerges 2 to 6 weeks after starting the medication, but can be difficult to diagnose due to its varied presentation and overlap with other conditions.
This article will explore a specific case highlighting the challenges of diagnosing levofloxacin-induced DRESS/DIHS in a patient with pre-existing autoimmune conditions. We'll delve into the symptoms, diagnostic process, and the importance of awareness among both patients and healthcare providers.
DRESS Cases and Levofloxacin
The European Medicines Agency’s CMDh scientific conclusions report a constant accumulation of DRESS cases associated with systemic levofloxacin use. A 2024 systematic review set out to identify and risk-stratify drugs that can cause DRESS. Its dataset included 610 studies published from 1991 to 2022, covering 2,122 validated cases attributed to 193 drugs; drugs were classified as high, intermediate, or low risk based on publication frequency.
DRESS History and Levofloxacin Reports
A historical overview says DRESS was first described by Saltzstein in 1959, while noting that similar illness may have been recognized as early as the 1940s after hydantoin was introduced. Levofloxacin-associated DRESS/DIHS has also appeared in published case reports. One report describes a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome; a separate Reactions Weekly report published in 2022 is identified as a levofloxacin DRESS case report.
Unmasking DRESS/DIHS: A Case Study
A 77-year-old woman with a history of systemic scleroderma (SSc), rheumatoid arthritis (RA), and Sjogren's syndrome (SjS) was admitted to the hospital with high fever, shortness of breath, and a widespread red rash (erythroderma). Prior to admission, she had been treated with intravenous levofloxacin for a cough and fever. While initial oral levofloxacin seemed to resolve her symptoms, they returned with greater intensity three weeks later.
- Erythroderma (widespread red rash)
- Lymphadenopathy (swollen lymph nodes)
- Eosinophilia (elevated eosinophil count)
- Elevated levels of soluble interleukin-2 receptor
- Reactivation of human herpes virus 6 (HHV-6)
Reviews on DRESS Diagnosis
A 2023 literature review and treatment algorithm recommends taking a thorough clinical history of suspected drugs when identifying a possible DRESS culprit. It says a skin biopsy may help with diagnosis and identifies patch testing as the test of choice for searching for the culprit drug. A 2025 comprehensive review describes its focus as recent research on DRESS pathogenesis, clinical features, diagnosis, confirmatory testing, and treatment.
DRESS Outcomes and Severe Complications
The DRESS Syndrome Foundation reports that most patients recover from the initial episode with prompt diagnosis and proper treatment. It also notes that severe cases can involve multi-organ failure. Fulminant liver failure is described as the most common cause of death, while heart, lung, and kidney failure may also occur. The source highlights myocarditis, or heart inflammation, as a particular concern.
Levofloxacin Case and Patient Experience
A 2015 report describes DRESS following levofloxacin exposure and characterizes DRESS as a severe cutaneous drug reaction that can be life-threatening. A CDC patient story recounts that the person had not known an antibiotic could leave an otherwise healthy person disabled at age 36. Together, these sources present the reaction through both a clinical case report and a patient’s account of its impact.
Levofloxacin and DRESS/DIHS: What You Need to Know
This case highlights the challenges of diagnosing DRESS/DIHS, especially when it is triggered by levofloxacin and occurs in patients with underlying autoimmune conditions. While allergy tests may be negative, clinicians should maintain a high index of suspicion based on clinical presentation and diagnostic criteria.
Reported Levofloxacin DRESS Cases
A 2022 case report describes a woman diagnosed with levofloxacin-induced DRESS based on clinical presentation and findings. Her levofloxacin therapy was discontinued, and she was treated with prednisone and corticosteroids. Another report concerns DRESS/DIHS in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome; its source snippet describes the reaction as potentially life-threatening and notes that levofloxacin had not previously been reported in the literature cited there.
DRESS/DIHS is often misdiagnosed due to overlap with other conditions. The RegiSCAR and Kardaun's scoring systems aid in diagnosis. DRESS/DIHS can mimic other conditions, making diagnosis difficult. Negative allergy tests do not rule out DRESS/DIHS.
If you experience fever, rash, swollen lymph nodes, or other unusual symptoms after taking levofloxacin, seek immediate medical attention. Awareness of this potential adverse reaction is crucial for prompt diagnosis and management, ultimately leading to better outcomes.